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The use of injectable scaffolding materials for in vivo tissue regeneration has raised
great interest in various clinical applications because it allows cell implantation
through minimally invasive surgical procedures. In case of cartilage repair, a tissue
engineered construct should provide a support for the cell and allow sustained in
situ delivery of bioactive factors capable of inducing cell differentiation into
chondrocytes. Pharmacologically active microcarriers (PAMs), made of
biodegradable poly(d,l-lactide-co-glycolide acid) (PLGA), are a unique system, which
combines these properties in an adaptable and simple microdevice. However, a
limitation of such scaffold is low and incomplete protein release that occurs using
the hydrophobic PLGA based microspheres. To circumvent this problem, we
developed a novel formulation of polymeric PAMs containing a P188 poloxamer,
which protects the protein from denaturation and may positively affect
chondrogenesis. This poloxamer was added as a free additive for protein
complexation and as a component of the scaffold covalently linked to PLGA. This
procedure allows getting a more hydrophilic scaffold but also retaining the
protective polymer inside the microcarriers during their degradation. The novel
PLGA-P188-PLGA PAMs presenting a fibronectin-covered surface allowed enhanced
MSC survival and proliferation. When engineered with TGFβ3, they allowed the
sustained release of 70% of the incorporated TGF-β3 over time. Importantly, they
exerted superior chondrogenic differentiation potential compared to previous FN-
PAM-PLGA-TGF-β3, as shown by an increased expression of specific cartilage
markers such as cartilage type II, aggrecan and COMP. Therefore, this microdevice
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